- Home
- JCI vs BMY Comparison
JCI vs BMY Comparison
Compare JCI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JCI | BMY |
|---|---|---|
| Founded | 1885 | 1887 |
| Country | Ireland | United States |
| Employees | N/A | 32500 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0B | 123.7B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | JCI | BMY |
|---|---|---|
| Price | $130.09 | $58.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $133.31 | $61.93 |
| AVG Volume (30 Days) | 3.6M | ★ 9.8M |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | 1.22% | ★ 4.28% |
| EPS Growth | ★ 99.60 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $9,902,000,000.00 | N/A |
| Revenue This Year | $7.66 | N/A |
| Revenue Next Year | $6.44 | N/A |
| P/E Ratio | $153.58 | ★ $17.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.03 | $42.52 |
| 52 Week High | $146.49 | $62.89 |
Technical Indicators
Market Signals| Indicator | JCI | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 45.35 |
| Support Level | $111.18 | $53.88 |
| Resistance Level | $146.49 | $62.47 |
| Average True Range (ATR) | 3.29 | 1.16 |
| MACD | -2.11 | -0.51 |
| Stochastic Oscillator | 4.56 | 13.25 |
Price Performance
Historical ComparisonAbout JCI Johnson Controls International plc
Following Johnson Controls' divestiture of its residential and light commercial HVAC businesses to Bosch in 2025, nearly all of its revenue comes from commercial HVAC (60%) and fire and security products and services (40%). A 2016 merger joined Johnson Controls' HVAC and Tyco's fire and security businesses with the premise that there is synergy in offering a broader variety of automation products and solutions to commercial buildings. We estimate Johnson Controls' pro forma revenue mix will be one-third products, one-third installation, and one-third services.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.